---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-049550"
form_type: "8-K"
ticker: "CTXR"
cik: "0001506251"
company_name: "Citius Pharmaceuticals, Inc."
filed_at: "2025-05-30T23:59:59+00:00"
generated_at: "2026-05-20T04:17:05.015514+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Citius Pharma receives Nasdaq delisting notice for bid price non-compliance

## Summary
- Received Nasdaq letter on May 29, 2025 for failing minimum $1 bid price for 33 consecutive business days.
- Not eligible for compliance period due to reverse stock split within prior year.
- Plans to appeal by June 5, 2025 to stay suspension; delisting would start June 9 without appeal.
- No assurance that Nasdaq will grant relief or that compliance can be regained.

## SEC filing metadata
- accession: 0001213900-25-049550
- form_type: 8-K
- ticker: CTXR
- cik: 0001506251
- company_name: Citius Pharmaceuticals, Inc.
- filed_at: 2025-05-30T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506251/000121390025049550/0001213900-25-049550-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506251/000121390025049550/ea0244023-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-049550
- JSON: https://secwatch.observer/filing/0001213900-25-049550.json
- Plain text: https://secwatch.observer/filing/0001213900-25-049550.txt

## Key facts
- Listing & Compliance Notices
  Citius Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(iv), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5810(c)(3)(A)(iv), 5810(c)(3)(A)
  source text: May 29, 2025, Citius Pharmaceuticals, Inc. (the “Company”) received a determination letter (the “Letter”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market notifying the Company that, based upon the closing bid price of the Company’s common stock for the prior 33 consecutive business days, the Company was not in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2). The Letter states that, pursuant to Nasdaq Listing Rule 5810(c)(3)(A)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1506251/000121390025049550/0001213900-25-049550-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.